BeStock  
Stocks › Biotechnology › CGEM

Cullinan Therapeutics CGEM

US equityMarket cap rank #3511Biotechnology
$8.89 −$0.18 (-1.98%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $8.96 +0.79%
Open$8.84
Prev close$9.07
Day range$8.80 – $9.46
Volume1.01M
Market cap$577.15M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$52.60M+5.4% YoY
Net profit-$49.39M+2.4% YoY
Diluted EPS-$0.74+3.9% YoY
Free cash flow-$43.08M-16.7% YoY
Operating cash flow-$43.08M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-47.6MDec '24$-48.5MMar '25$-70.1MJun '25$-50.6MSep '25$-50.7MDec '25$-49.7MMar '26$-53.7MJun '26$-49.4MSep '26

Diluted EPS by quarter

-0.73Dec '24-0.74Mar '25-1.07Jun '25-0.77Sep '25-0.77Dec '25-0.75Mar '26-0.81Jun '26-0.74Sep '26

Free cash flow by quarter

$-36.6MDec '24$-43.2MMar '25$-57.6MJun '25$-36.9MSep '25$-38.1MDec '25$-46.0MMar '26$-38.2MJun '26$-43.1MSep '26

Annual revenue

$0.0FY20$18.9MFY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-55.5%
Return on assets-50.4%
Return on invested capital-59.6%
Current ratio7.43
Liabilities / assets12.8%
Cash & investments$289.57M
Total debt$1.15M
Net cash (debt)$288.43M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $52.60M $57.25M $53.70M $241.65M $55.26M
Selling and Admin Expenses $12.43M $12.82M $11.57M $54.25M $12.31M
-General & Admin Expense $12.43M $12.82M $11.57M $54.25M $12.31M
Research & Development $40.17M $44.44M $42.12M $187.40M $42.95M
Operating Profit -$52.60M -$57.25M -$53.70M -$241.65M -$55.26M
Net Non-Operating Interest Income (Expense) $3.29M $3.65M $4.10M $22.21M $4.62M
Non-Operating Interest Income $3.29M $3.65M $4.10M $22.21M $4.62M
Other Income (Expense) -$76,000.00 -$98,000.00 -$62,000.00 -$443,000.00 -$69,000.00
Other Non-Operating Income (Expenses) -$76,000.00 -$98,000.00 -$62,000.00 -$443,000.00 -$69,000.00
Pretax Profit -$49.39M -$53.70M -$49.66M -$219.88M -$50.71M
Net Profit -$49.39M -$53.70M -$49.66M -$219.88M -$50.71M
Profit from Continuing Operations -$49.39M -$53.70M -$49.66M -$219.88M -$50.71M
Net Income to Parent Company -$49.39M -$53.70M -$49.66M -$219.88M -$50.71M
Net Income to Common Stockholders -$49.39M -$53.70M -$49.66M -$219.88M -$50.71M
Basic EPS -$0.74 -$0.81 -$0.75 -$3.36 -$0.77
Diluted EPS -$0.74 -$0.81 -$0.75 -$3.36 -$0.77
Tax – – – $0.00 –
Minority Interests – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $322.56M $363.79M $402.98M $448.37M $448.37M
Total Current Assets $298.15M $341.97M $361.41M $386.76M $386.76M
Cash and Cash Equivalents & Short-Term Investments $289.57M $334.54M $351.89M $377.90M $377.90M
-Cash and Cash Equivalents $88.26M $78.64M $75.08M $88.33M $88.33M
-Short Term Investments $201.31M $255.90M $276.80M $289.56M $289.56M
Other Current Assets $8.58M $7.44M $9.52M $8.86M $8.86M
Total Non-Current Assets $24.41M $21.81M $41.58M $61.62M $61.62M
Net PPE $2.21M $2.50M $2.78M $3.05M $3.05M
-Gross PPE $2.21M $2.50M $2.78M $4.02M $4.02M
Investments and Advances $21.90M $19.02M $38.50M $58.27M $58.27M
-Held to Maturity Securities $21.90M $19.02M $38.50M $58.27M $58.27M
Other Non-Current Assets $297,000.00 $297,000.00 $297,000.00 $297,000.00 $297,000.00
Total Liabilities $41.28M $42.03M $36.81M $39.64M $39.64M
Total Current Liabilities $40.13M $40.63M $35.15M $37.74M $37.74M
Payables $9.24M $10.70M $8.14M $9.63M $9.63M
-Accounts Payable $1.14M $3.73M $2.51M $841,000.00 $841,000.00
-Other Payable $8.10M $6.97M $5.63M $8.78M $8.78M
Current Accrued Expenses $21.28M $22.80M $21.94M $16.39M $16.39M
Short-Term Debt and Capital Lease Obligation $859,000.00 $666,000.00 $725,000.00 $780,000.00 $780,000.00
-Current Capital Lease Obligation $859,000.00 $666,000.00 $725,000.00 $780,000.00 $780,000.00
Other Current Liabilities $1.47M $1.53M $1.35M $996,000.00 $996,000.00
Total Non-Current Liabilities $1.15M $1.41M $1.66M $1.90M $1.90M
Long Term Debt and Capital Lease Obligation $1.15M $1.41M $1.66M $1.90M $1.90M
-Long Term Capital Lease Obligation $1.15M $1.41M $1.66M $1.90M $1.90M
Total Equity $281.28M $321.75M $366.17M $408.73M $408.73M
Stockholders' Equity $281.28M $321.75M $366.17M $408.73M $408.73M
Capital Stock $6,000.00 $6,000.00 $6,000.00 $6,000.00 $6,000.00
-Common Stock $6,000.00 $6,000.00 $6,000.00 $6,000.00 $6,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.02B $1.01B $1.00B $995.82M $995.82M
Retained Earnings -$740.87M -$691.48M -$637.78M -$588.12M -$588.12M
Gains/Losses Not Affecting Retained Earnings -$652,000.00 -$134,000.00 $127,000.00 $1.02M $1.02M
-Accumulated Depreciation – – – -$969,000.00 -$969,000.00
Minority Interests – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$43.08M -$38.22M -$46.05M -$175.75M -$38.11M
Net cash flow from continuing operations -$43.08M -$38.22M -$46.05M -$175.75M -$38.11M
Net Income from Continuing Operations -$49.39M -$53.70M -$49.66M -$219.88M -$50.71M
Depreciation & Depletion & Amortization $53,000.00 $79,000.00 $79,000.00 $311,000.00 $79,000.00
Change in Working Capital -$1.67M $7.51M -$3.30M $14.08M $6.14M
-Change in Prepaid Assets -$1.15M $2.09M -$662,000.00 $6.90M $840,000.00
-Change in Payables and Accrued Expense -$520,000.00 $5.43M -$2.64M $7.19M $5.30M
Net cash flow from investing $51.64M $40.68M $32.41M $179.99M $22.39M
Net Cash Flow from Continuing Investing Activities $51.64M $40.68M $32.41M $179.99M $22.39M
Net Investment Purchase and Sale $51.64M $40.68M $32.41M $180.04M $22.40M
Financing Cash Flow $1.06M $1.10M $380,000.00 $1.09M $715,000.00
Net Cash Flow from Continuing Financing Activities $1.06M $1.10M $380,000.00 $1.09M $715,000.00
Proceeds from Stock Option Exercised $1.06M $1.10M $380,000.00 $1.09M $715,000.00
Ending Cash Balance $88.26M $78.64M $75.08M $88.33M $88.33M
Net Change in Cash $9.62M $3.56M -$13.25M $5.33M -$15.00M
Beginning Cash Balance $78.64M $75.08M $88.33M $83.01M $103.34M
Free Cash Flow -$43.08M -$38.22M -$46.05M -$175.80M -$38.12M
Net PPE Purchase and Sale – – – -$49,000.00 -$11,000.00
Net Common Stock Issuance – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on CGEM.

Sign in to join the discussion.

Scroll to Top